🇺🇸

US SEC Filing Intelligence

· daily

All HHS Contracts — April 01, 2026

Emergent BioSolutions Inc. benefits from a $256M HHS contract for botulism antitoxin, with $188M outlayed and potential extension to 2029, signaling multi-year revenue stability in biodefense. Non-competed award to its Canadian subsidiary underscores U.S. government reliance on the firm for critical countermeasures. Investors should monitor cost overrun risks in the firm fixed price structure and foreign ownership scrutiny amid geopolitical tensions.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 01, 2026

NASA drives 67% ($2.06B) of $3.06B mega contracts, awarding long-term space engineering/logistics to RTX/Raytheon ($1.22B), Lockheed ($301M), TRAX ($406M), and Caltech ($134M) through 2026-2029, signaling robust U.S. space priorities. Defense/environmental (HII $446M, Sevenson $180M) and biodefense (Emergent $256M) add diversified bullish exposure with 8-18 year visibilities. Low outlays (avg. 40% funded) flag appropriation risks, but $100M+ options and follow-on potential favor primes.

8 total filings
· daily

High-Value Federal Grants ($5M+) — April 01, 2026

NASA dominates with $2.06B (67%) of $3.06B in high-value contracts, signaling sustained federal investment in space instrumentation, vehicles, and logistics through 2029, primarily bullish for RTX, Lockheed Martin, and support firms. Long-term cost-plus structures provide revenue visibility but tie payouts to performance amid funding risks. Defense, biotech, environmental remediation, and construction also secure multi-year commitments, with 7/8 bullish signals indicating broad stability in federal spending.

8 total filings
· daily

General Federal Contracts — April 01, 2026

NASA dominates with $2.06B across 4 contracts (67% of total), signaling robust long-term funding for space instruments, vehicles, and logistics through 2029, bullish for RTX, Lockheed Martin, and support firms. Broader $3.06B in bullish awards to defense, biotech, remediation, and construction firms highlight sustained federal spending on strategic priorities despite execution risks from extended timelines (avg. 8+ years). Institutional investors should prioritize aerospace/defense exposure while monitoring funding outlays averaging 35% complete.

8 total filings
· daily

All NASA Contracts — April 01, 2026

NASA's $2.06B in contracts dominated by RTX Raytheon ($1.22B, 59%) signal strong long-term demand for space vehicle components and instruments through 2029, with Goddard SFC awarding 75% of value. Lockheed Martin and Trax add multi-year revenue visibility to 2026 and 2024, respectively, while Caltech's JPL neutral funding supports optical comms to 2027. Investors gain backlog clarity for aerospace primes amid cost-plus structures, but low outlays (avg. 37% obligated) flag funding risks.

4 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 01, 2026

Across the 15 filings in the USA S&P 500 Technology stream (with broader exposure via context), dominant themes include M&A completions and amendments (CWBC merger, CYH asset sale, LUNR acquisition), financing activities (NOW credit agreement, Cottonwood/Lafayette stock raises, MU tender offers), and mixed financial results highlighted by MLP's 68% YoY revenue growth offset by 43% wider net loss. Period-over-period trends show revenue surges in select areas (MLP leasing +1,000% YoY, land sales +68% YoY) but declines elsewhere (CYH pro forma revenues -327M, MLP unidentified segment -41% YoY), with no dominant margin compression but operational losses persisting. Tech-specific signals are positive: ServiceNow's credit facility enhances liquidity, Micron's debt tender manages liabilities, Intuitive Machines advances $800M acquisition integration. Portfolio-level patterns reveal 4/15 filings with strong YoY revenue growth (>50%), 5 with net loss expansions, and forward catalysts like Immunic's Phase 3 data by end-2026. Critical implications: M&A scale-ups boost assets (CWBC to $5B), but pro forma declines flag revenue risks; actionable now for post-deal trading opportunities amid neutral insider/institutional patterns.

6 high priority 9 medium 15 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 01, 2026

Across 18 NASDAQ-100 related SEC filings from April 1, 2026, dominant themes include transformative M&A activity (CWBC merger, KDP JDE Peet's acquisition, LUNR $800M Lanteris buy, CYH $459M asset sale) signaling consolidation in banking, beverages, space, and healthcare, with combined entities boasting $5B+ assets or $16B+ revenues. Period-over-period trends show revenue growth in land development (MLP +68% YoY to $19.5M, leasing +1000% YoY to $5.8M) and financing inflows (FF +100% YoY cash to $161.4M), but persistent operating losses (FF $331M FY2025, MLP net loss +43% to $10.6M) and pro forma declines (CYH revenues - $327M). Positive catalysts include Nasdaq compliance regains (Immunic), product validations (AITX), and equity turnarounds (FF stockholders' equity +$7.7M from negative), while neutral proxy filings (UCBI, Intellicheck) and institutional ownership (WMG 13G 5.1%) indicate routine governance. Portfolio-level patterns reveal mixed sentiment (7 positive/mixed growth, 9 neutral), with capital raises via stock sales (Cottonwood $3.6M) and debt optimization supporting turnarounds amid Nasdaq bid price pressures (FF notice). Market implications favor M&A beneficiaries for near-term synergies but flag liquidity risks in loss-making firms.

8 high priority 10 medium 18 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — April 01, 2026

In a very quiet session for activist and institutional activity with only one filing, Darlington Partners Capital Management and affiliates disclosed a new passive 5.1% stake (7,551,884 shares) in Warner Music Group Corp. (WMG) Class A Common Stock via Schedule 13G filed April 1, 2026, based on holdings as of March 25, 2026. This represents crossing the 5% threshold with shares held for investment adviser clients, certifying no intent to influence control or change the board, maintaining neutral sentiment (materiality 7/10). Shares outstanding stable at 146,965,855 per WMG's 10-Q for Q/E December 31, 2025, with no period-over-period changes in ownership structure noted. No forward-looking guidance, insider trading, capital allocation shifts, M&A, or operational metrics detailed in the filing, underscoring passive institutional conviction amid a lack of broader sector activity. Market implications include mild validation of WMG's valuation without activist pressure, potentially supporting stability in media/entertainment ownership trends. No portfolio-level patterns emerge from the single filing, but highlights selective institutional interest post-Q4 2025.

1 medium 1 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (broadly including banks, funds, REITs, and related sectors), overarching themes reveal robust M&A/divestiture activity (10+ deals like CWBC merger, CHS $459M sale, Duke $2.48B divestiture), mixed financial performance with bifurcation—revenue grew +17-52% YoY in 9 firms (avg +28%) but plunged -25-78% in 8 (avg -52%), and margin expansions (+900bps in AIDX, +140bps ASE) offsetting compressions. Capital allocation favors returns ($766M WY cash to SH, Cal-Maine $24.3M buyback/$0.36 div), but small caps/biotechs show dilution risks via warrants/placements (e.g., LABT $7.5M pref, Cadrenal inducement). Forward-looking catalysts include growth targets (WY $1.5B EBITDA by 2030, Lamb Weston raised FY26 guidance $6.45-6.55B sales), fund conversions (TCW Jun 2026), and AGMs (WY May 15). Sparse insider data shows no major sales/buys, but mgmt conviction via promotions/div hikes. Portfolio-level: Financials/funds stable (Nuveen $120M Q1 subs), while cyclicals/commodities volatile; actionable now—favor M&A beneficiaries amid reg risks (LFTD hemp bans).

32 high priority 18 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the S&P 500 Consumer Staples stream (April 1, 2026), dominant themes include proxy season acceleration with 20+ DEF 14A/DEFA14A filings for May 2026 annual meetings emphasizing director elections, say-on-pay, and auditor ratifications, alongside mixed Q3/FY2025 results showing organic sales resilience (e.g., Conagra +2.4% organic vs -1.9% reported YoY) but widespread margin compression and EBITDA declines in staples like Lamb Weston (-27% adj EBITDA despite +3% sales YoY). M&A activity surges with Keurig Dr Pepper's 96.22% acquisition of JDE Peet’s (EUR 9.9B 2025 sales) for a YE2026 coffee spin-off and Cyclerion's dilutive merger (1.5% ownership retention). Period-over-period trends reveal revenue volatility (Safe & Green +3,900% YoY to $8.2M but loss widened to $16M; Rocky Mountains -50.5% Q1 YoY), improving losses in biotech (Monopar -12% YoY), and capital returns via dividends (Armour $0.24/share, Lamb $0.38) and buybacks (IPG $50M, DFIN $172M record). Forward-looking signals mixed: Lamb Weston raised FY2026 sales/EBITDA midpoints, Conagra narrowed to margin high-end ~11.0-11.5%, with catalysts like BioXcel FDA PDUFA Nov 14, 2026. Leadership churn prominent (6+ CFO/GC changes), no widespread insider selling/buying patterns noted. Portfolio implications: Favor M&A/transforming staples (KDP) over margin-squeezed peers; monitor May proxies for governance shifts amid sector resilience via organic growth offsetting inflation.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 01, 2026

Across 50 SEC filings from S&P 500 Industrials and related entities on April 1, 2026, sentiment is predominantly mixed (14/50), with positive tones in M&A completions, dividend declarations, and strong FY2025 results (e.g., L3Harris $21.9B revenue + backlog growth), offset by revenue declines (avg -10% YoY in 7 firms like Innate Pharma -78%, Bassett -2.2%) and widening losses (e.g., Safe & Green net loss +79% to $16M). Period-over-period trends show revenue growth in 6/20 quantifiable filers (e.g., URBN +11.1%, Enphase $1.5B), margin expansions in outperformers (L3Harris + to 15.8%, URBN + to 36%), but compression elsewhere (Bassett -80bps); capital allocation favors dividends (5 declarations, e.g., Global Net Lease $0.19/share) and buybacks (URBN $177M, IPG $50M). M&A activity peaks with Community West-USFO merger ($185M), property dispositions boosting liquidity (Medalist cash to $19M), and capital raises (Charlotte's Web $75M BAT commitment). Insider activity sparse, but management conviction seen in approvals (Golden Entertainment 98% MTA vote). Forward catalysts cluster in May-Jun 2026 proxy/AGM season (L3Harris May 11, Enphase May 13), signaling portfolio rotation opportunities amid volatile direct listings (Lakewood-Amedex) and delisting risks (Safe & Green, Faraday). Overall, industrials exhibit resilient capital returns but bifurcated growth, favoring selective longs in defense/energy storage over cyclicals.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 01, 2026

The USA S&P 500 Energy stream reflects a very quiet session dominated by routine proxy filings from ONEOK and SunCoke Energy, with neutral sentiment across three filings (materiality 4-6/10) focusing on standard governance matters like director elections, auditor ratifications, and say-on-pay votes ahead of May 2026 virtual AGMs. Hall Chadwick Acquisition Corp's 8-K stands out as the most significant development (positive sentiment, 8/10 materiality), announcing a non-binding LOI with REEcycle Holdings for a potential de-SPAC transaction, signaling early M&A activity in energy-adjacent recycling. No explicit period-over-period financial trends (YoY/QoQ revenue, margins) or insider trading activity disclosed across filings, indicating stable but unremarkable operational momentum; board metrics at SunCoke show consistent 2025 activity with 10 board meetings and 15 committee meetings at >75% attendance versus typical sector norms of 8-12 meetings. Forward-looking elements highlight auditor engagements through Dec 31, 2026, and AGM catalysts on May 14-20, 2026. Portfolio-level themes include strong board independence (SunCoke: 5/6 independent directors) and governance continuity, implying low near-term volatility but limited alpha catalysts beyond Hall Chadwick's deal potential. Overall implications: defensive positioning for Energy sector amid proxy season, with watch for shareholder vote outcomes.

3 high priority 1 medium 4 total filings
· daily

US Material Events SEC 8-K Filings — April 01, 2026

Across 50 SEC filings from April 1, 2026, dominant themes include a surge in M&A completions and amendments (12/50 filings, e.g., CWBC-UBFO merger, Ondas-World View acquisition), executive transitions (15+ CFO/CEO/Director changes, mostly positive appointments), and credit facility expansions/amendments (10+ cases boosting liquidity, e.g., Cousins $1.2B revolver, Enova multiple increases). Period-over-period pro forma trends show mixed results: divestitures drove revenue declines averaging ~30-55% YoY (Duke -15%, Medalist -55%, CHS -$327M) but gains/debt reductions (Duke net income +102% to $887M, CHS +$138M after-tax gain); no broad margin compression but operational income drops in divested units. Forward-looking catalysts cluster in Q2-Q3 2026 (merger closings, systems conversions, JDE delisting Apr 30). Portfolio-level patterns indicate financial sector consolidation (banks/REITs), AI/defense tuck-ins, and improved capital access amid neutral-to-positive sentiment (65% positive/neutral). Critical implications: enhanced liquidity supports growth, but dilution risks in biotech/SPACs and revenue gaps from sales signal monitoring for earnings impacts.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 01, 2026

Across 50 SEC filings from Dow Jones 30-related entities and peers on April 1, 2026, overarching themes include robust M&A activity (e.g., Community West merger completion, SharonAI $1.25BN deal, Ondas acquisition), mixed 10-K results with strong revenue growth (avg +100% YoY in growth outliers like Amaze Holdings +558%, Charlie's +169%) but persistent net losses and impairments, and proxy season ramp-up with 15+ AGMs in May 2026. Period-over-period trends show revenue expansion in 12/20 10-Ks (e.g., URBAN +11.1% to $6.2B, ASIAFIN +51.6%), but margin compression or widened losses in 14 cases (e.g., NIKE gross profit -3.1% YoY Q3), alongside positive capital returns like Lamb Weston $0.38 dividend and Las Vegas Sands $2.94B buybacks/dividends. Critical developments feature SPAC mergers progressing (Brag House extension to May 29), Nasdaq delisting risks (Brand House), and forward guidance raises (Lamb Weston FY2026 sales $6.45-6.55B). Portfolio-level patterns indicate sector rotation toward AI/tech (SharonAI, BSTR Bitcoin treasury) amid blue-chip stability, with 8 positive sentiments on deals vs 18 mixed on financials, signaling selective opportunities in consolidations despite operational pressures.

30 high priority 20 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 01, 2026

Across 50 SEC filings dated April 1, 2026, dominant themes include elevated M&A and SPAC activity (10+ filings: Haymaker, Community West, Cyclerion, Golden Entertainment), mixed financial results with 12 companies showing YoY revenue growth averaging +45% (e.g., Charlie's +169%, RH +8%) offset by sharp declines in 8 firms averaging -38% (Cal-Maine -53%, OLB -32%), and margin expansions in select industrials/biotechs (ASE gross +140 bps to 17.7%) amid compressions elsewhere. Proxy statements (Circle, Weyerhaeuser) highlight positive 2025 recaps and growth strategies, while biotechs/pharmas (Lakewood-Amedex, IceCure, Adaptin) pursue listings/raises amid losses. Capital returns strong in resources (Weyerhaeuser $766M, +5% dividend) and buybacks (News Corp $1B program), but impairments and regulatory risks (LFTD $23M goodwill) pressure consumer/health sectors. Portfolio-level: 60% mixed sentiment, with M&A driving near-term catalysts but cyclical downturns in ag/food/eggs signaling caution. Implications: Favor M&A plays and dividend growers; monitor May shareholder votes for comp approvals/guidance.

33 high priority 17 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 01, 2026

The 50 filings reveal polarized performance in the Consumer Discretionary stream, with standout revenue growth in apparel/retail like URBN (+11.1% YoY sales to $6.2B, op income +27.8%) and niche players (ASIAFIN +51.6% YoY, Safe & Green x40 to $8.2M) contrasting sharp declines in food/retail (Cal-Maine Q3 sales -53% YoY, net income -90.1%; Bassett -2.2% sales, op income -52.9%) and EVs (SHF -50% revenue). Margin trends mixed: expansions in URBN (gross to 36.0%) but compressions averaging -100bps across 5 reporters (Bassett -80bps, Nike gross -3.1% Q3 YoY). Capital allocation emphasizes returns with buybacks (URBN $177M/3.7M shares, Cal-Maine $24.3M) and dividends (multiple payable Apr-May 2026). Forward catalysts cluster Q2: earnings (O'Reilly, Blue Owl May), AGMs (URBN June 3, Cinemark May 14), M&A closes (Cal-Maine Creighton). Regulatory risks (LFTD hemp bans threatening 52% sales by Nov 2026) and listing issues (Faraday Nasdaq bid <1) heighten volatility. Portfolio implication: favor resilient retail growth plays amid cyclical pressures.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 01, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (with broader US equity context), dominant themes include a wave of proxy statements (DEF 14A/DEFA14A) for May 2026 annual meetings signaling governance focus amid neutral sentiment; aggressive M&A in regional banks adding $1B+ in assets (e.g., Fulton, CVB, Associated Banc); and mixed biotech performance with 7/12 healthcare firms reporting widened YoY net losses (avg +70%) from R&D ramps (e.g., Forte +95% expenses) offset by cash infusions and pipeline catalysts. Period-over-period trends show healthcare revenue volatility (Interpace Q4 -26% YoY GAAP but thyroid +14%; iSpecimen tissue rev -54% mix share) contrasted by strong bank deposit/loan growth post-mergers; capital allocation leans toward accretive deals over buybacks (News Corp $1B program outlier). Insider activity limited to routine tax-related sales (CCEP PDMRs net zero accumulation). Critical developments: Biotech catalysts like TuHURA Phase 3 enrollment mid-2027 and Forte 2026 readouts; bank expansions positioning for organic growth; implications favor monitoring healthcare turnarounds amid high burn rates while bank M&A offers stability in uncertain markets.

26 high priority 24 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 01, 2026

Across 50 DEF 14A proxy statements, US companies showcase resilient 2025 performance with strong capital returns totaling billions (e.g., Las Vegas Sands $2.94B via buybacks/dividends, Weyerhaeuser $766M cash returned), dividend increases (Weyerhaeuser +5% YoY to $0.21/share), and buybacks (Donnelley $172M record), amid performance-tied executive pay hikes (Coeur Mining CEO +51.5% YoY to $6.65M on 133% AIP payout). Period-over-period trends reveal revenue growth (IPG Photonics +3% YoY first since 2021, L3Harris $21.9B), EBITDA records (Sands $5.23B, Weyerhaeuser ~$1.0B), and TSR outperformance (Ventas >35% vs S&P 500 double), though mixed signals include flat segments (Sands Macao EBITDA flat YoY) and LTI shortfalls (Advance Auto 0% payout 3rd year). Forward-looking catalysts cluster in May-June 2026 virtual AGMs for say-on-pay votes and director elections, with growth targets like Weyerhaeuser's $1.5B incremental EBITDA by 2030 and Sands' $8B MBS expansion. No widespread insider selling or pledges noted (e.g., Postal Realty 0% pledged), signaling management alignment; REITs/utilities/defense lead relative performance. Implications: Bullish on real assets (timber/REITs) and backlog-heavy sectors; monitor gaming/mining for regional softness and governance proposals.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 01, 2026

The IPO Pipeline stream features two key SEC filings: Expro Ltd's S-4 for redomiciliation to Cayman Islands with NYSE listing under XPRO, signaling structural optimization for growth, and TRIC Global's S-1 for an imminent IPO as a nascent Connect platform developer. Expro exhibits strong positive sentiment (9/10 materiality) with 10.5% holder Oak Hill Advisors committing to vote in favor, no operational changes, and minimal 1% dilution risk from withdrawals, positioning it for enhanced liquidity and flexibility. TRIC, incorporated December 2025, reports neutral sentiment (9/10 materiality) with zero revenue, expenses, compensation, facilities, patents, or governance structures for FY ended Dec 31, 2025, highlighting early-stage risks. No YoY/QoQ financial trends available across filings, but TRIC's $0 metrics vs Expro's established structure underscore a bifurcation in pipeline maturity. Portfolio-level theme: 1/2 filings show positive restructuring catalysts amid governance voids in new entrants, implying selective opportunities in relistings over pure IPOs. Market implications include near-term NYSE catalyst for Expro and prolonged scrutiny for TRIC's S-1 effectiveness.

2 high priority 2 total filings